The U.S. health regulator has issued a warning letter to Fresenius Kabi Oncology for violation of manufacturing norms at its Kalyani facility in West Bengal. The U.S. Food and Drug Administration (USFDA) has also cautioned that unless corrective measures are taken up, it “may withhold approval of any new applications or supplements listing Fresenius Kabi, Kalyani, as an API manufacturer.’’ Besides, the USFDA warned that failure to correct the violations might result in ban of imports of products manufactured in the plant to the U.S. — PTI